{
    "clinical_study": {
        "@rank": "26925", 
        "arm_group": [
            {
                "arm_group_label": "Personalized variable dose of glucocorticoids arm", 
                "arm_group_type": "Experimental", 
                "description": "Use of personalized variable dose of glucocorticoids according to a rating scale starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, inhaled corticosteroid (ICS)+long-acting beta2-agonist (LABA), LAMA, SABA, and other physical treatments."
            }, 
            {
                "arm_group_label": "Experiential dose of glucocorticoids arm", 
                "arm_group_type": "Other", 
                "description": "Use of glucocorticoids at doses according to normal clinical practice, together with other necessary treatments, including antibiotics, ICS+LABA, LAMA, SABA, and other physical treatments."
            }, 
            {
                "arm_group_label": "Fixed dose of glucocorticoids arm", 
                "arm_group_type": "Other", 
                "description": "Use of fixed term of glucocorticoids (40mg) starting from the first day of hospitalization for 5 days, together with other necessary treatments, including antibiotics, ICS+LABA, LAMA, SABA, and other physical treatments."
            }
        ], 
        "brief_summary": {
            "textblock": "Our hypothesis is that in acute exacerbated Chronic Obstructive Pulmonary Disease (AECOPD),\n      personalized variable dose glucocorticoid treatment will result in superior clinical outcome\n      when compared to fixed or experiential dose therapy."
        }, 
        "brief_title": "Personalized Variable Versus Experiential or Fixed Dose Glucocorticoid Therapy in AECOPD", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Obstructive Pulmonary Disease", 
        "condition_browse": {
            "mesh_term": [
                "Lung Diseases", 
                "Respiration Disorders", 
                "Pulmonary Disease, Chronic Obstructive", 
                "Lung Diseases, Obstructive"
            ]
        }, 
        "detailed_description": {
            "textblock": "Treatment with glucocorticoid for acute exacerbations of COPD results in the improvement of\n      clinical outcomes. However, the optimal doses of glucocorticoid for each individual patient\n      has not been determined. According to GOLD Report 2014, a dose of 40 mg prednisone per day\n      for 5 days is recommended (Evidence B), although there are insufficient data to provide firm\n      conclusions concerning the optimal duration of corticosteroid therapy of acute exacerbations\n      of COPD. Our purpose is to compare clinical outcomes of personalized or fixed or\n      experiential dose of glucocorticoid in patients with acute exacerbations of COPD."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Exacerbation of COPD as defined by the presence of at least 2 of the following:\n             change in baseline dyspnea, cough, or sputum quantity or purulence.\n\n        Exclusion Criteria:\n\n          -  Signs of severe exacerbation (arterial pH < 7.26 or pCO2 > 9.3 kPa)\n\n          -  History of asthma\n\n          -  Significant or unstable co-morbidity\n\n          -  Participated in another study 4 weeks before admission\n\n          -  Previously randomized to this study\n\n          -  Known hypersensitivity to prednisolone\n\n          -  Inability to give written informed consent\n\n          -  Radiological diagnosis of pneumonia\n\n          -  Estimated survival of less than 6 months due to severe comorbidity\n\n          -  Use of glucocorticoid within 1 month before admission"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "360", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 22, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02147015", 
            "org_study_id": "VIP"
        }, 
        "intervention": {
            "arm_group_label": [
                "Personalized variable dose of glucocorticoids arm", 
                "Experiential dose of glucocorticoids arm", 
                "Fixed dose of glucocorticoids arm"
            ], 
            "intervention_name": "Glucocorticoids", 
            "intervention_type": "Drug", 
            "other_name": "Corticosteroid"
        }, 
        "intervention_browse": {
            "mesh_term": "Glucocorticoids"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Acute Exacerbations", 
            "Corticosteroids", 
            "Chronic Obstructive Pulmonary Disease", 
            "Doses"
        ], 
        "lastchanged_date": "May 25, 2014", 
        "location": {
            "contact": {
                "last_name": "Lin Zhou, Medical Doctor", 
                "phone": "86-23-68757001"
            }, 
            "facility": {
                "address": {
                    "city": "Chongqing", 
                    "country": "China", 
                    "state": "Chongqing", 
                    "zip": "400042"
                }, 
                "name": "Daping Hospital"
            }, 
            "investigator": {
                "last_name": "Guoqiang Cao, Medical Doctor", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Personalized Variable Versus Experiential or Fixed Dose Corticosteroids Therapy in Hospitalized Patients With Acute Exacerbations of Chronic Obstructive Pulmonary Disease", 
        "other_outcome": {
            "measure": "Hospital costs", 
            "safety_issue": "No", 
            "time_frame": "up to 1 month"
        }, 
        "overall_contact": {
            "email": "cgq1963@163.com", 
            "last_name": "Guoqiang Cao, Medical Doctor", 
            "phone": "86-23-68757781"
        }, 
        "overall_contact_backup": {
            "email": "lili10119@126.com", 
            "last_name": "Li Li, Medical Doctor", 
            "phone": "86-23-68757793"
        }, 
        "overall_official": {
            "affiliation": "Daping Hospital, Third Military Medical University", 
            "last_name": "Guoqiang Cao, Medical Doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: National Health and Family Planning Commision", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "death from any cause;\nadmission to the intensive care unit;\nreadmission to the hospital because of COPD\nthe necessity to intensify pharmacologic treatment", 
            "measure": "Treatment failure", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "10465169", 
                "citation": "Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999 Aug 7;354(9177):456-60."
            }, 
            {
                "PMID": "20551406", 
                "citation": "Lindenauer PK, Pekow PS, Lahti MC, Lee Y, Benjamin EM, Rothberg MB. Association of corticosteroid dose and route of administration with risk of treatment failure in acute exacerbation of chronic obstructive pulmonary disease. JAMA. 2010 Jun 16;303(23):2359-67. doi: 10.1001/jama.2010.796. PubMed"
            }, 
            {
                "PMID": "23695200", 
                "citation": "Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, Duerring U, Henzen C, Leibbrandt Y, Maier S, Miedinger D, M\u00fcller B, Scherr A, Schindler C, Stoeckli R, Viatte S, von Garnier C, Tamm M, Rutishauser J. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013 Jun 5;309(21):2223-31. doi: 10.1001/jama.2013.5023. PubMed"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02147015"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
            "investigator_full_name": "Guoqiang Cao", 
            "investigator_title": "Vice Chair of Department of Respiratory Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "length of hospital stay", 
            "safety_issue": "Yes", 
            "time_frame": "1 month"
        }, 
        "source": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}